Kaveri Pohlman
Stock Analyst at Clear Street
(3.70)
# 2,124
Out of 5,184 analysts
235
Total ratings
35.1%
Success rate
5.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintained: Buy | $18 → $10 | $1.24 | +706.45% | 3 | Nov 11, 2026 | |
| ORKA Oruka Therapeutics | Reiterated: Buy | $131 → $105 | $104.56 | +0.42% | 6 | Oct 26, 2026 | |
| AVBP ArriVent BioPharma | Reiterated: Buy | n/a | $14.16 | - | 4 | Oct 25, 2026 | |
| PVLA Palvella Therapeutics | Reiterated: Buy | $220 | $174.08 | +26.38% | 4 | Oct 20, 2026 | |
| QTTB Q32 Bio | Initiated Coverage: Buy | $38 | $9.34 | +306.85% | 1 | Oct 1, 2026 | |
| SGMT Sagimet Biosciences | Reiterated: Buy | $28 | $10.83 | +158.54% | 5 | Sep 30, 2026 | |
| EVMN Evommune | Reiterated: Buy | $28 → $23 | $7.65 | +200.65% | 4 | Sep 9, 2026 | |
| GPCR Structure Therapeutics | Reiterated: Buy | $99 | $21.41 | +362.40% | 3 | Sep 8, 2026 | |
| JBIO Jade Biosciences | Rated: Buy | $25 → $48 | $15.60 | +207.69% | 3 | Sep 4, 2026 | |
| PTGX Protagonist Therapeutics | Reiterated: Buy | $173 | $135.90 | +27.30% | 7 | Aug 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $45 → $69 | $45.12 | +52.93% | 2 | Aug 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $46 → $47 | $11.73 | +300.68% | 20 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $55 → $68 | $51.55 | +31.91% | 3 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $1.50 | +500.00% | 2 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $31 | $17.84 | +73.77% | 1 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 | $12.62 | +454.68% | 6 | Jun 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 → $29 | $15.31 | +89.42% | 3 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $533 → $680 | $432.79 | +57.12% | 3 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $1.19 | +908.40% | 2 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $11 → $20 | $15.61 | +28.12% | 3 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $32 → $12 | $12.76 | -5.96% | 4 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $6.43 | +179.94% | 1 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $4.35 | +175.86% | 17 | Nov 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $71.74 | n/a | 8 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $55.80 | n/a | 18 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.34 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.70 | n/a | 4 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $18.95 | n/a | 30 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $22.26 | n/a | 13 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.99 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $38.59 | n/a | 13 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 | $1.13 | n/a | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.000001 | n/a | 6 | Nov 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $16 → $8 | $1.98 | n/a | 3 | Jul 6, 2022 |
Zura Bio
Nov 11, 2026
Maintained: Buy
Price Target: $18 → $10
Current: $1.24
Upside: +706.45%
Oruka Therapeutics
Oct 26, 2026
Reiterated: Buy
Price Target: $131 → $105
Current: $104.56
Upside: +0.42%
ArriVent BioPharma
Oct 25, 2026
Reiterated: Buy
Price Target: n/a
Current: $14.16
Upside: -
Palvella Therapeutics
Oct 20, 2026
Reiterated: Buy
Price Target: $220
Current: $174.08
Upside: +26.38%
Q32 Bio
Oct 1, 2026
Initiated Coverage: Buy
Price Target: $38
Current: $9.34
Upside: +306.85%
Sagimet Biosciences
Sep 30, 2026
Reiterated: Buy
Price Target: $28
Current: $10.83
Upside: +158.54%
Evommune
Sep 9, 2026
Reiterated: Buy
Price Target: $28 → $23
Current: $7.65
Upside: +200.65%
Structure Therapeutics
Sep 8, 2026
Reiterated: Buy
Price Target: $99
Current: $21.41
Upside: +362.40%
Jade Biosciences
Sep 4, 2026
Rated: Buy
Price Target: $25 → $48
Current: $15.60
Upside: +207.69%
Protagonist Therapeutics
Aug 31, 2026
Reiterated: Buy
Price Target: $173
Current: $135.90
Upside: +27.30%
Aug 21, 2026
Rated: Buy
Price Target: $45 → $69
Current: $45.12
Upside: +52.93%
Aug 14, 2026
Rated: Buy
Price Target: $46 → $47
Current: $11.73
Upside: +300.68%
Aug 6, 2026
Rated: Buy
Price Target: $55 → $68
Current: $51.55
Upside: +31.91%
Aug 3, 2026
Reiterated: Buy
Price Target: $9
Current: $1.50
Upside: +500.00%
Aug 3, 2026
Reiterated: Buy
Price Target: $31
Current: $17.84
Upside: +73.77%
Jun 22, 2026
Reiterated: Buy
Price Target: $70
Current: $12.62
Upside: +454.68%
May 7, 2026
Reiterated: Buy
Price Target: $21 → $29
Current: $15.31
Upside: +89.42%
May 6, 2026
Reiterated: Buy
Price Target: $533 → $680
Current: $432.79
Upside: +57.12%
Mar 31, 2026
Reiterated: Buy
Price Target: $12
Current: $1.19
Upside: +908.40%
Mar 6, 2026
Rated: Buy
Price Target: $11 → $20
Current: $15.61
Upside: +28.12%
Jan 20, 2026
Downgraded: Hold
Price Target: $32 → $12
Current: $12.76
Upside: -5.96%
Dec 11, 2025
Reiterated: Buy
Price Target: $18
Current: $6.43
Upside: +179.94%
Nov 26, 2025
Reiterated: Buy
Price Target: $12
Current: $4.35
Upside: +175.86%
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $71.74
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $55.80
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $2.34
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $1.70
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $18.95
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $22.26
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $4.99
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $38.59
Upside: n/a
Apr 29, 2024
Reiterated: Buy
Price Target: $21
Current: $1.13
Upside: n/a
Nov 23, 2022
Downgraded: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
Jul 6, 2022
Rated: Buy
Price Target: $16 → $8
Current: $1.98
Upside: n/a